A large proportion of CML patients attain a prolonged molecular response, and in approximately half of the patients who are treated with ABL TKIs and achieve a certain period of sustained deep molecular response, ABL TKI administration can be discontinued and treatment-free remission can be achieved1. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.